Working... Menu

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00068952
Recruitment Status : Completed
First Posted : September 16, 2003
Last Update Posted : April 1, 2008
Information provided by:

Brief Summary:
The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: Edotecarin Drug: Temozolomide Drug: Carmustine (BCNU) Drug: Lomustine (CCNU) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy
Study Start Date : August 2003
Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy

Secondary Outcome Measures :
  1. To assess measures of tumor control To evaluate measures of clinical benefit To assess the safety profile of edotecarin To assess the PK profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have biopsy-proven GBM. First relapse (progression or recurrence) of GBM after surgery (or biopsy) and treatment with radiotherapy (conventional fractionated external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy)
  • Must have past biopsy samples available for central pathology review
  • Must have evidence on Gd-MRI of progressive/recurrent disease
  • Must have measurable disease on Gd-MRI obtained within 14 days prior to start of study treatment
  • Must be at least 18 years of age
  • Must have a Karnofsky Performance Status score of at least 70
  • If being treated with steroids, the steroid dose must be stable or decreasing for 1 week prior to randomization
  • If being treated with anticonvulsants, must have no change in the type of anticonvulsants for 2 weeks prior to randomization
  • All acute toxic effects (except for alopecia) of any prior treatment must have resolved or are no greater than grade 1 (NCI Common Toxicity Criteria, Version 2.0)
  • Baseline laboratory data must be within the following limits: absolute neutrophil count at least 1500; platelets at least 100,000; hemoglobin at least 9.0 g/dL; serum creatinine no greater than 1.5 mg/dL, total serum bilirubin no greater than 1.5 times the upper limit of the normal range; SGOT and SGPT no greater than 2.5 times the upper limit of the normal range; albumin at least 3.0 g/dL, serum or urine pregnancy test (for females of childbearing potential) negative within 7 days prior to start of study treatment
  • At least 6 weeks must have elapsed since completion of prior nitrosurea therapy; at least 4 weeks since completion of prior temozolomide therapy
  • Must have written informed consent
  • Must be able and willing to comply with study procedures
  • 	Must have received prior treatment with radiotherapy (conventional fractionated external beam) and (neo)adjuvant/concurrent chemotherapy (with a temozolomide- or a nitrosurea-based containing )regimen for GBM

Exclusion Criteria:

  • Must not have received prior treatment (except for surgical debulking) of first relapse (progression or recurrence) of GBM
  • Must not have received prior treatment with another topoisomerase-I inhibitor (e.g. irinotecan, topotecan, rubitecan)
  • Must not have had radiosurgery or radiotherapy within 1 month prior to randomization
  • Must not have had prior brachytherapy or chemotherapy wafer implantation
  • Must not have had prior high-dose chemotherapy with bone marrow or stem cell support
  • Must not receive concomitant treatment with any other investigational agent or anti-cancer treatment during the study
  • Must not be currently enrolled in another therapeutic clinical trial for the treatment of GBM
  • Must not currently (or in the past 5 years) have other malignancies (except for adequately treated basal cell or squamous cell skin cancer or non-invasive cervical cancer)
  • Must not have any of the following in the past 6 months: myocardial infarction (heart attack), severe/unstable angina, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (stroke), or transient ischemic attack (TIA)
  • Must not have had any of the following in the past 2 months: pulmonary embolus (blood clot in lungs), deep venous thrombosis (blood clot in veins), or other significant thromboembolic event
  • Must not have an ongoing cardiac dysrhythmia (abnormal heart rhythm) of grade 2 or higher (NCI Common Toxicity Criteria, Version 2.0)
  • Must not have known human immunodeficiency virus (HIV) infection
  • Must not be pregnant or breastfeeding. Patients (male and female) must be surgically sterile (or postmenopausal for females) or must agree to use effective contraception during the period of study treatment
  • Must not be inappropriate for entry into the study, in the judgment of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00068952

  Hide Study Locations
Layout table for location information
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States
United States, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas, United States
United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States
United States, Florida
Pfizer Investigational Site
Orlando, Florida, United States
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Evanston, Illinois, United States
United States, Kentucky
Pfizer Investigational Site
Edgewood, Kentucky, United States
Pfizer Investigational Site
Edgweood, Kentucky, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States
United States, New Hampshire
Pfizer Investigational Site
Lebanon, New Hampshire, United States
United States, New Jersey
Pfizer Investigational Site
Edison, New Jersey, United States
Pfizer Investigational Site
Summit, New Jersey, United States
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States
United States, Virginia
Pfizer Investigational Site
Charlottesville, Virginia, United States
Australia, New South Wales
Pfizer Investigational Site
St. Leonards, New South Wales, Australia
Australia, Victoria
Pfizer Investigational Site
East Bentleigh, Victoria, Australia
Pfizer Investigational Site
Clayton, Australia
Pfizer Investigational Site
Graz, Austria
Pfizer Investigational Site
Wien, Austria
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada
Canada, British Columbia
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Canada, Manitoba
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Canada, New Brunswick
Pfizer Investigational Site
Moncton, New Brunswick, Canada
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Split, Croatia
Pfizer Investigational Site
Zagreb, Croatia
Czech Republic
Pfizer Investigational Site
Hradec Kralove, Czech Republic
Pfizer Investigational Site
Praha 5, Czech Republic
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
Nantes St. Herblain, France
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Mainz, Germany
Pfizer Investigational Site
Regensburg, Germany
Pfizer Investigational Site
Tuebingen, Germany
Pfizer Investigational Site
Bangalore, India
Pfizer Investigational Site
Bologna, Italy
Pfizer Investigational Site
Padova, Italy
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation
South Africa
Pfizer Investigational Site
Cape Town, South Africa
Pfizer Investigational Site
Pretoria, South Africa
Pfizer Investigational Site
Badalona, Spain
Pfizer Investigational Site
Hospitalet de Llobregat, Spain
Pfizer Investigational Site
Oviedo, Spain
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer

Layout table for additonal information Identifier: NCT00068952     History of Changes
Other Study ID Numbers: EDOAGL-8725-001
First Posted: September 16, 2003    Key Record Dates
Last Update Posted: April 1, 2008
Last Verified: March 2008

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents